louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03775122: TAES Improve the Function of Respiration and Circulation on Elderly Patients Undergoing Colonoscopy Procedure
Official title: Transcutaneous Acupoint Electrical Stimulation Improve the Function of Respiration and Circulation on Elderly Patients Undergoing Colonoscopy Procedure：A Randomized-controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Respiratory Depression
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2018-12-13
Enrollment: 20
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To explore the effectiveness of transcutaneous acupuncture electrical stimulation (TAES), a non-invasive modality in improvement of the function of respiration and circulation on elder patient during colonoscopy.

Detailed description: To assess the function of respiratory and circulation before precondition, during colonoscopy and end of the procedure, blood cortisol and catecholamine levels were measured also.The incidence of airway support, application of vasoactive drug or atropine during procedure were recorded in the meantime.

Eligibility criteria: Inclusion Criteria:

1. patients aged 65 or older
2. American Society of Anesthesiologists (ASA) grade I\~II
3. consent and voluntary participation in this experiment
4. patients under colonoscopy
5. none allergic to propofol and fentanyl
6. airway assessment for none difficult airway

Exclusion Criteria:

1. Allergic to propofol, fentanyl.
2. ASA is greater than or equal to grade 3
3. Abnormal respiratory tract may cause severe respiratory obstruction
4. unsatisfactory control of hypertension, systolic pressure over 160 millimeter of mercury (mmHg) or diastolic pressure over 100 mmHg
5. Hypotension, systolic pressure below 90 mmHg, heart rate (HR) \<50bpm or \>100bpm

Primary outcomes:
measure: The percentage of oxygen saturation
timeFrame: from 20min before lay down to 24hours after performance
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Diansan Su
state: Shanghai
Study officials:
affiliation: Renji Hospital,School of Medicine,Shanghai Jiaotong University
name: Yu Weifeng, Dr
role: STUDY_DIRECTOR
References:
citation: Chen Y, Gong Y, Huai X, Gu X, Su D, Yu W, Xie H. Effects of transcutaneous electrical acupuncture point stimulation on peripheral capillary oxygen saturation in elderly patients undergoing colonoscopy with sedation: a prospective randomized controlled trial. Acupunct Med. 2021 Aug;39(4):292-298. doi: 10.1177/0964528420960479. Epub 2020 Nov 30.
Clinical trial NCT06243822: Ketamine Versus Propofol as ICU Sedation
Official title: Hemodynamic Effects of Ketamine Compared With Propofol as Continuous ICU Sedation in Mechanically Ventilated Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Ketamine
Propofol
Sedation
Mechanical Ventilation
Lead sponsor: Menoufia University
Sponsor class: OTHER
First posted: 2024-02-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: this study is to assess the hemodynamic profile of ketamine compared with propofol in critically ill, mechanically ventilated adult Patients study will be carried out on 100 mechanically ventilated patients who received one sedative agent propofol or ketamine The patients will be randomized into two equal groups to receive either ketamine or propofol Group 1 (Ketamine group): ketamine is initiated at 0.5 mg/kg/h and titrated by 0.25 mg/kg/h every 15 minutes to a maximum dosage of 4 mg/kg/h to achieve appropriate sedation. Group 2 (Propofol group): Propofol is initiated at 0.3 to 0.6 mg /kg/hr. and titrated by 0.3 to 0.6 mg/kg/h every 5 to 10 minutes up to a maximum dosage of 4.5 to 4.8 mg/kg/hr. to achieve appropriate sedation.


Eligibility criteria: Inclusion Criteria:

* mechanically ventilated, and receive sedation with continuous infusion propofol, or ketamine for at least 24 hours

Exclusion Criteria:

* Receiving propofol or ketamine concurrently.

  * Transferred from an outside hospital on sedation.
  * Receiving ketamine for an indication other than sedation.
  * Daily intake of opioids.
  * Contraindication to any drug used in the study.

Primary outcomes:
measure: heart rate
timeFrame: every 15 min for the first hour then every hour for next six hours then every six hours for 48 hours
measure: mean arterial blood pressure
timeFrame: every 15 min for the first hour then every hour for next six hours then every six hours for 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: Menoufia University
state: Menoufia
Study officials:
affiliation: Menoufia University
name: Mostafa Saieed Mansour, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06951022: The Effect of Sujok Therapy on Urinary Incontinence and Quality of Life in Postmenopausal Women
Official title: The Effect of Sujok Therapy on Urinary Incontinence and Quality of Life in Postmenopausal Women
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Urinary Incontinence (UI)
Postmenopause
Keywords: Su Jok Therapy
Urinary Incontinence
Quality of Life
Postmenopausal Women
Lead sponsor: Inonu University
Sponsor class: OTHER
First posted: 2025-04-30
Enrollment: 120
Sex: FEMALE
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants in the experimental group will receive Su Jok seed therapy using apple seeds applied to the hand point that reflects the bladder. Participants will be trained to perform the therapy themselves and will apply it daily for 15 days. They will be reminded via daily messages and monitored for adherence.
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the effect of Su Jok therapy, a complementary medicine practice, on urinary incontinence and quality of life among postmenopausal women. A total of 120 participants will be included in the study, with 60 in the intervention group and 60 in the control group. Participants in the intervention group will receive Su Jok seed therapy applied to the hand reflex points corresponding to the bladder. The therapy will be administered by the researcher and then taught to the participants, who will continue the application for 15 days. Assessments will be conducted at baseline, day 15, and day 30 using validated questionnaires.


Eligibility criteria: Inclusion Criteria:

Women under 65 years of age in the postmenopausal period, Literate, No speech or communication impairment

Exclusion Criteria:

Use of diuretics

Presence of nephrotic syndrome

Diagnosis of diabetes or hypertension

Symptoms of urinary tract infection

Diagnosis of psychiatric illness

History of urinary tract surgery

Diagnosed urinary prolapse

Failure to complete the intervention

Primary outcomes:
measure: Change in urinary incontinence symptoms measured by the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)
timeFrame: At baseline, 15 days and 30 days after intervention
measure: Change in quality of life measured by the Incontinence Quality of Life Scale (I-QOL)
timeFrame: At baseline, 15 days and 30 days after intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Battalgazi̇
country: Turkey
facility: Inonu University
state: Malatya
Study officials:
References:
Clinical trial NCT00917722: Deep Brain Stimulation of the Subthalamic Nucleus (STN) and Cognitive Control
Official title: Deep Brain Stimulation of the STN and Cognitive Control: A Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson's Disease
Keywords: Parkinson's Disease
STN DBS
Deep Brain Stimulation
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2009-06-10
Enrollment: 12
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Only patients who already have implants will be invited to participate in this study, and no changes to stimulator settings are made for the purposes of this study.

Brief summary: In this study, the investigators will follow patients who have had stimulators implanted, at their usual clinic follow-up appointments 3, 6, 9 and 12 months after surgery. It is typical at these appointments for patients to be off medication and for the stimulators to be turned off to observe disease progress and test stimulator effectiveness. Also as part of standard clinical practice, stimulator settings are adjusted for optimal benefit to motor symptoms. Only patients who already have implants will be invited to participate in this study, and no changes to stimulator settings are made for the purposes of this study. Stimulator settings are changed based on clinical evaluation of motor symptoms, and this study has no bearing on how stimulators will be set nor how often they will be set.


Eligibility criteria: Inclusion Criteria:

* Meet criteria for "definite" Parkinson's Disease (PD)
* STN stimulators on both sides (right and left)
* Surgery done at Washington University within 2 years

Exclusion Criteria:

* Significant visual deficits (e.g. double vision, untreated eyelid apraxia, blepharospasm) Must be able to see screen
* Secondary Parkinsonism (drug-induced or other known etiologies)
* Brain injury or defect: history of serious head injury, stroke, encephalitis, defect found on brain imaging
* Early severe dementia (within first year of onset) or on cholinesterase inhibitors
* Pre-surgical Mini Mental Status exam score \< 24
* Significant current psychiatric diagnoses (such as depression or psychosis) or on neuroleptics

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Tamara G Hershey, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01143922: Role of Intraoperative Ultrasound in Gastrointestinal (GI) Malignancies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ultrasonography
Gastrointestinal Disease
Malignancy
Keywords: Intraoperative ultrasound
GI tract malignancies
modality
ultrasound
staging modality
Lead sponsor: All India Institute of Medical Sciences
Sponsor class: OTHER
First posted: 2010-06-15
Enrollment: 100
Sex: ALL
Minimum age (years): 10
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients with GI tract malignancies undergoing surgery

Brief summary: Currently available investigating modalities like CT scans, MRI etc although have a high accuracy in staging of gastrointestinal(GI) tract malignancies, are not correct in all cases . The aim of this study is to assess the role of intraoperative ultrasound as a modality to increase the staging accuracy of GI tract malignancies


Eligibility criteria: Inclusion Criteria:

* Patients with GI tract malignancies

Exclusion Criteria:

* Patients who refuse consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New Delhi
country: India
facility: AIIMS
state: Delhi
Study officials:
References:
Clinical trial NCT03807622: ClearSight System CHN Study
Official title: A Prospective, Nonrandomized, Non-interventional Trial to Evaluate ClearSight System Cardiac Output in China
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patient With Clinically Indicated Invasive Monitoring
Keywords: Elective Major Cardiothoracic
Mitral Valve Surgery
Coronary Artery Bypass Grafting
Lead sponsor: Edwards Lifesciences
Sponsor class: INDUSTRY
First posted: 2019-01-17
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing elective major cardiothoracic surgery with an indwelling PA catheter. The surgical intervention includes, but is not limited to, mitral valve surgery or coronary artery bypass grafting.

Brief summary: The purpose of this clinical trial is to demonstrate that cardiac output (CO) as determined with the Clinical Platform (Model:EV1000A, Software Version:1.9) in a noninvasive manner is comparable to CO as determined by Pulmonary Artery Catheter (PAC) thermodilution (TD). The results of this study may be used for registration and regulatory submissions.


Eligibility criteria: Inclusion Criteria:

* Subjects must be at least 18 years of age
* Subjects provide written informed consent prior to trial procedures
* Subjects' height and weight must be accurately obtained prior to study start.

Exclusion Criteria:

* Aortic or tricuspid valve regurgitation
* Aortic stenosis or aneurysms
* Cardiac rhythm disorder
* Patients with extreme contraction of the smooth muscle in the arteries and arterioles in the lower arm and hand, such as may be present in patients with Raynaud's or Buerger's disease or with extremely cold hands
* Inability to place the finger cuff appropriately due to subject anatomy or condition
* Known pregnancy
* Patients being treated with an intra-aortic balloon pump
* Patient is currently participating in an investigational drug or another device study that clinically interferes with the study endpoints
* Intracardiac shunt

Primary outcomes:
measure: Cardiac Output using the Non-invasive ClearSight System
timeFrame: Expected to last no more than 6 hours
Secondary outcomes:
measure: The percentage error (PE) between the ClearSight System CO and TD
timeFrame: Expected to last no more than 6 hours
Other outcomes:
Locations:
city: Xicheng
country: China
facility: Fuwai Cardiovascular Disease Hospital, Chinese Academy of Medical Sciences, Beijing
state: Beijing
city: Wuhan
country: China
facility: Wuhan Asia Heart Hospital
state: Hubei Sheng
city: Heping
country: China
facility: Tianjin Chest Hospital
state: Tianjin
Study officials:
References:
citation: Wang Y, Huang W, Han J, Tian Y, Wang C, Li L. A comparison of ClearSight noninvasive cardiac output and pulmonary artery bolus thermodilution cardiac output in cardiac surgery patients. Perioper Med (Lond). 2022 Jun 9;11(1):24. doi: 10.1186/s13741-022-00248-1.
Clinical trial NCT05829122: Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty
Official title: Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty for Aphakia and Traumatic Mydriasis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Aphakia
Mydriasis
Keywords: Aphakia
Mydriasis
Lead sponsor: Changzhou Second People's Hospital affiliated with Nanjing Medical University
Sponsor class: OTHER
First posted: 2023-04-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, best corrected visual acuity, intraocular pressure, pupil diameter, corneal endothelial cell count, fundus examination, and photophobia score, were collected. Those who met the recruitment criteria underwent modified iris cerclage pupilloplasty. The modified iris cerclage pupilloplasty was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.


Eligibility criteria: Inclusion Criteria:

* diagnosis of aphakia
* permanently dilated pupils
* history of phacoemulsification and pars plana vitrectomy surgeries for lens dislocation after blunt trauma

Exclusion Criteria:

* iris defects
* severe diseases such as cyclodialysis cleft, uncontrolled IOP, retinal detachment
* poorly controlled systemic diseases such as diabetes and hypertension
* corneal endothelial cell counts of \<1000/mm2
* \<6 months of follow-up

Primary outcomes:
measure: best corrected visual acuity
timeFrame: preoperatively
measure: best corrected visual acuity
timeFrame: 6 months postoperatively
measure: intraocular pressure
timeFrame: preoperatively
measure: intraocular pressure
timeFrame: 6 months postoperatively
measure: pupil diameter
timeFrame: preoperatively
measure: pupil diameter
timeFrame: 6 months postoperatively
measure: corneal endothelial cell count
timeFrame: preoperatively
measure: corneal endothelial cell count
timeFrame: 6 months postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Changzhou
country: China
facility: Preoperatively and 6 Months Postoperatively
state: Jiangsu
Study officials:
References:
Clinical trial NCT04679922: Fascia Lata Allograft Versus Subepithelial Connective Tissue Grafts in the Peri-Implant Mucosal Thickness Enhancement.
Official title: Fascia Lata Allograft Versus Subepithelial Connective Tissue Grafts in the Peri-Implant
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Implant Tissue Failure
Lead sponsor: Tanta University
Sponsor class: OTHER
Collaborators: name: Tanta University
First posted: 2020-12-22
Enrollment: 20
Sex: ALL
Minimum age (years): 30
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this, randomized clinical trial is to determine the clinical efficacy of fascia lata allograft in terms of peri-implant mucosal augmentation, as compared to autologous sub epithelial connective tissue graft, clinically and histologically in human adults .

Detailed description: The aim of this, randomized clinical trial is to determine the clinical efficacy of fascia lata allograft in terms of peri-implant mucosal augmentation, as compared to autologous sub epithelial connective tissue graft, clinically and histologically in human adults .

The hypothesis of the study is that a similar gain in peri implant mucosal thicknesses will be obtained in sites treated by either a sub epithelial connective tissue graft or a newly developed fascia lata allograft in clinically and histologically in human.

The objective of this study will be to evaluate the efficacy of the peri-implant mucosal thickness enhancement following either subepithelial connective tissue grafts or human Fascia Lata Allograft placed simultaneously with dental implant placement.

Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Participants will be randomized to the control (simultaneous SCTGs) or test (simultaneous FLA) group.

Eligibility criteria: Inclusion Criteria:

Ability to maintain good oral hygiene as evidenced in recall visits. Aged 30 to 55 years. Stable periodontal condition and missing one single tooth (maxillary anterior teeth and premolars) with adjacent teeth present and thin mucosal phenotype (\< 2mm bucco- lingual thickness).

Exclusion Criteria:

Uncontrolled diabetes mellitus. Females who were pregnant, or attempting to become pregnant, and nursing mothers.

Acute infection in the area intended for implant placement.

Primary outcomes:
measure: Peri-Implant Mucosal Thickness
timeFrame: Measure changes in mucosal thickness around dental implant at base line and after 6 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Faculty of dentistry Tanta University
Study officials:
References:
Clinical trial NCT03369522: Development of an Epileptic Seizure Detection Algorithm by Continuous Analysis of the Electrocardiogram
Official title: Development of an Epileptic Seizure Detection Algorithm by Continuous Analysis of the Electrocardiogram
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Seizures
Epilepsy
Electrocardiography
Keywords: seizure detection
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2017-12-12
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with epilepsy for whom a long-term video-EEG monitoring is required as part of their management

Brief summary: The aim of our project is to develop an epileptic seizure detection algorithm based on the the continuous analysis of the Electrocardiogram

Detailed description: In a first step, the team will build a multi-parametric algorithm on existing records issued from the Epilepsy Monitoring Units. Each selected record will be analyzed by EMU medical team in order to detect seizure on the EEG. The algorithm will adapt in order to obtain the best sensitivity and specificity regarding seizure detection.

in a second step,algorithm will validate on a cohort of other recordings in patients with epilepsy

Eligibility criteria: Inclusion Criteria:

* patients with epilepsy
* with a long-term video-EEG recording
* 1 (or more) seizure (s) recorded
* onset seizure clearly defined on the basis of the EEG

Exclusion Criteria:

* bad quality of the Electrocardiogram recording
* pace-maker
* non sinus rhythm

Primary outcomes:
measure: ROC curve for seizure detection
timeFrame: 24 months
Secondary outcomes:
measure: Time of detection of seizures
timeFrame: 24 months
measure: ROC curve for Psychogenic seizure detection
timeFrame: 24 months
Other outcomes:
Locations:
city: Béthune
country: France
facility: Ch Bethune
city: Lille
country: France
facility: Hôpital Roger Salengro, CHU
city: Salouël
country: France
facility: Chu Amiens Salouël
city: Valenciennes
country: France
facility: Ch de Valencienne
Study officials:
affiliation: University Hospital, Lille
name: William Szurhaj, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00207922: The Polarization and Expression of Chemokine Receptors of T Help Cell in the Pathogenesis of Acute and Chronic GVHD
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hematopoietic Stem Cell Transplantation, Graft-Versus-Host Disease
Keywords: cytokine
T-cell
chemokine
graft-versus-host disease
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2005-09-21
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: The purpose of this study is to see the correlation of polarization and the expresison of chemokine receptors of T help cells after allogeneic hematopoietic stem cell transplantation and clinical course graft-versus-host disease.


Eligibility criteria: Inclusion Criteria:

* patient received allogeneic stem cell transplantation at CMUH
* can be regularly followed at CMUH

Exclusion Criteria:

* patient who do not want to enter in this study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
name: Su-Peng Yeh, MD
role: PRINCIPAL_INVESTIGATOR
References: